scholarly journals Serial endometrial thickness and risk of non‐endometrial hormone‐dependent cancers in postmenopausal women in UK Collaborative Trial of Ovarian Cancer Screening

2020 ◽  
Vol 56 (2) ◽  
pp. 267-275 ◽  
Author(s):  
M. Burnell ◽  
A. Gentry‐Maharaj ◽  
C. Glazer ◽  
C. Karpinskyj ◽  
A. Ryan ◽  
...  
2017 ◽  
Vol 117 (5) ◽  
pp. 619-627 ◽  
Author(s):  
Usha Menon ◽  
Alistair J McGuire ◽  
Maria Raikou ◽  
Andy Ryan ◽  
Susan K Davies ◽  
...  

Cancers ◽  
2020 ◽  
Vol 12 (7) ◽  
pp. 1931
Author(s):  
Aleksandra Gentry-Maharaj ◽  
Oleg Blyuss ◽  
Andy Ryan ◽  
Matthew Burnell ◽  
Chloe Karpinskyj ◽  
...  

Longitudinal CA125 algorithms are the current basis of ovarian cancer screening. We report on longitudinal algorithms incorporating multiple markers. In the multimodal arm of United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS), 50,640 postmenopausal women underwent annual screening using a serum CA125 longitudinal algorithm. Women (cases) with invasive tubo-ovarian cancer (WHO 2014) following outcome review with stored annual serum samples donated in the 5 years preceding diagnosis were matched 1:1 to controls (no invasive tubo-ovarian cancer) in terms of the number of annual samples and age at randomisation. Blinded samples were assayed for serum human epididymis protein 4 (HE4), CA72-4 and anti-TP53 autoantibodies. Multimarker method of mean trends (MMT) longitudinal algorithms were developed using the assay results and trial CA125 values on the training set and evaluated in the blinded validation set. The study set comprised of 1363 (2–5 per woman) serial samples from 179 cases and 181 controls. In the validation set, area under the curve (AUC) and sensitivity of longitudinal CA125-MMT algorithm were 0.911 (0.871–0.952) and 90.5% (82.5–98.6%). None of the longitudinal multi-marker algorithms (CA125-HE4, CA125-HE4-CA72-4, CA125-HE4-CA72-4-anti-TP53) performed better or improved on lead-time. Our population study suggests that longitudinal HE4, CA72-4, anti-TP53 autoantibodies adds little value to longitudinal serum CA125 as a first-line test in ovarian cancer screening of postmenopausal women.


2015 ◽  
Vol 33 (18) ◽  
pp. 2062-2071 ◽  
Author(s):  
Usha Menon ◽  
Andy Ryan ◽  
Jatinderpal Kalsi ◽  
Aleksandra Gentry-Maharaj ◽  
Anne Dawnay ◽  
...  

Purpose Cancer screening strategies have commonly adopted single-biomarker thresholds to identify abnormality. We investigated the impact of serial biomarker change interpreted through a risk algorithm on cancer detection rates. Patients and Methods In the United Kingdom Collaborative Trial of Ovarian Cancer Screening, 46,237 women, age 50 years or older underwent incidence screening by using the multimodal strategy (MMS) in which annual serum cancer antigen 125 (CA-125) was interpreted with the risk of ovarian cancer algorithm (ROCA). Women were triaged by the ROCA: normal risk, returned to annual screening; intermediate risk, repeat CA-125; and elevated risk, repeat CA-125 and transvaginal ultrasound. Women with persistently increased risk were clinically evaluated. All participants were followed through national cancer and/or death registries. Performance characteristics of a single-threshold rule and the ROCA were compared by using receiver operating characteristic curves. Results After 296,911 women-years of annual incidence screening, 640 women underwent surgery. Of those, 133 had primary invasive epithelial ovarian or tubal cancers (iEOCs). In all, 22 interval iEOCs occurred within 1 year of screening, of which one was detected by ROCA but was managed conservatively after clinical assessment. The sensitivity and specificity of MMS for detection of iEOCs were 85.8% (95% CI, 79.3% to 90.9%) and 99.8% (95% CI, 99.8% to 99.8%), respectively, with 4.8 surgeries per iEOC. ROCA alone detected 87.1% (135 of 155) of the iEOCs. Using fixed CA-125 cutoffs at the last annual screen of more than 35, more than 30, and more than 22 U/mL would have identified 41.3% (64 of 155), 48.4% (75 of 155), and 66.5% (103 of 155), respectively. The area under the curve for ROCA (0.915) was significantly (P = .0027) higher than that for a single-threshold rule (0.869). Conclusion Screening by using ROCA doubled the number of screen-detected iEOCs compared with a fixed cutoff. In the context of cancer screening, reliance on predefined single-threshold rules may result in biomarkers of value being discarded.


Cancer ◽  
1991 ◽  
Vol 68 (3) ◽  
pp. 458-462 ◽  
Author(s):  
J. R. Van Nagell ◽  
P. D. Depriest ◽  
L. E. Puls ◽  
E. S. Donaldson ◽  
H. H. Gallion ◽  
...  

Maturitas ◽  
1992 ◽  
Vol 15 (1) ◽  
pp. 87
Author(s):  
J.R Van Nagell ◽  
P.D DePriest ◽  
L.E Puls ◽  
E.S Donaldson ◽  
H.H Gallion ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document